|
13.01.2025 16:19:38
|
Bicycle Therapeutics Announces Topline Phase 1 Data For Zelenectide Pevedotin Plus Pembrolizumab
(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The stock is currently up 13%.
The company also announced recent accomplishments and outlined strategic priorities and anticipated milestones for 2025.
"Bicycle Therapeutics made significant advances across all aspects of our business in 2024. Notably, we drove important clinical progress of our targeted therapeutics in solid tumors, including greatly expanding the number of patients who could potentially benefit from our lead therapy zelenectide pevedotin, advanced our emerging pipeline of novel radiopharmaceuticals and strengthened our financial position and operational capabilities to advance our strategic priorities," said CEO Kevin Lee.
Zelenectide pevedotin, a Bicycle Toxin Conjugate, has significant potential to treat Nectin-4 cancers. 65% overall response rate (ORR) (13/20) among all efficacy-evaluable patients, and a 50% ORR (10/20) among patients with confirmed responses.
Nachrichten zu Bicycle Therapeutics Limited (spons. ADRs)
| Keine Nachrichten verfügbar. |
Analysen zu Bicycle Therapeutics Limited (spons. ADRs)
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Meta Platforms
NEU✅ Microsoft
inklusive Rebalancing:
❌ Arthur J. Gallagher & Co
❌ Progressive
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Bicycle Therapeutics Limited (spons. ADRs) | 13.01 | 0.93% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI fester -- DAX wenig bewegt -- US-Börsen uneins -- Börsen in Fernost letztlich uneinig - Nikkei stabilWährend sich der heimische Aktienmarkt fester zeigt, kommt der deutsche Leitindex zur Wochenmitte nicht vom Fleck. Die US-Börsen finden zur Wochenmitte keine gemeinsame Richtung. Auch die asiatischen Indizes gaben indes überwiegend nach, lediglich der Nikkei hielt sich knapp im Plus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |